无接触多极双极射频消融与手术切除治疗直径2至5厘米单发肝细胞癌的比较
单中心研究比较2012至2016年141例直径2至5厘米单发肝细胞癌患者接受无接触多极双极射频消融(NTM-RFA)或手术切除(SR)的结局,经逆概率治疗加权后比较128例。SR组并发症发生率更高(67.9% vs 50.0%,p=0.042)且住院更长,NTM-RFA组系统化复发率更高(3年27.8% vs 3.3%,p=0.008),局部复发率无显著差异(p=0.065),总生存和无病生存相似。
要点
- SR组并发症发生率67.9%高于NTM-RFA组50.0%(p=0.042),住院时间更长(12天 vs 7天,p<0.001)。
- NTM-RFA组3年系统化复发率27.8%高于SR组3.3%(p=0.008),局部复发率无显著差异(p=0.065)。
- 两组3年总生存(86.7% vs 91.4%,p=0.954)和无病生存(40.8% vs 56.4%,p=0.119)相似。
核心结论
- 与SR相比,NTM-RFA治疗单发中等大小肝细胞癌的并发症更少、系统化复发更多,局部复发率无显著差异。
- 多数肝内复发患者仍适合挽救治疗,两种治疗后的长期肿瘤学结果相当。
研究设计与样本
- 2012年至2016年单中心纳入141例直径2至5厘米单发肝细胞癌患者,接受NTM-RFA或SR治疗。
- 采用逆概率治疗加权(IPTW)后比较128例患者的结局。
主要发现
- 79例接受NTM-RFA,62例接受SR;IPTW后两组多数基线特征均衡,包括肿瘤大小、位置、病因、肝病严重程度和甲胎蛋白水平。
- SR组并发症发生率67.9% vs NTM-RFA组50.0%(p=0.042),住院时间12天(IQR 8-13) vs 7天(IQR 5-9)(p<0.001)。
- 1年和3年局部复发率:NTM-RFA组5.5%和10.0%,SR组1.9%和1.9%(p=0.065)。
- 1年和3年系统化复发率(治疗段内或距治疗部位2厘米内相邻段):NTM-RFA组7.4%和27.8%,SR组1.9%和3.3%(p=0.008)。
- 3年总生存率NTM-RFA组86.7% vs SR组91.4%(p=0.954),3年无病生存率NTM-RFA组40.8% vs SR组56.4%(p=0.119)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: No-touch multibipolar radiofrequency ablation (NTM-RFA) represents a novel therapy that surpasses standard RFA for hepatocellular carcinoma (HCC), but it has not been compared to surgical resection (SR). We aimed to compare the outcomes of NTM-RFA and SR for intermediate-sized HCC. METHODS: Between 2012 and 2016, 141 patients with solitary HCC ranging from 2 to 5 cm were treated by NTM-RFA or SR at a single-center. The outcomes of 128 patients were compared after using inverse probability of treatment weighting (IPTW). RESULTS: Seventy-nine patients had NTM-RFA and 62 had SR. After IPTW, the two groups were well-balanced for most baseline characteristics including tumor size, location, etiology, severity of underlying liver disease and alpha-fetoprotein level. Morbidity was higher (67.9% vs. 50.0%, p = 0.042) and hospital stay was longer (12 [IQR 8-13] vs. 7 [IQR 5-9] days, p <0.001) after SR. Local recurrence rates at one and three years were 5.5% and 10.0% after NTM-RFA and 1.9% and 1.9% after SR, respectively (p = 0.065). The rates of systematized recurrence (within the treated segment or in an adjacent segment within a 2 cm distance from treatment site) were higher after NTM-RFA (7.4% vs. 1.9% at one year, 27.8% vs. 3.3% at three years, p = 0.008). Most patients with recurrence were eligible for rescue treatment, resulting in similar overall survival (86.7% after NTM-RFA, 91.4% after SR at three years, p = 0.954) and disease-free survival (40.8% after NTM-RFA, 56.4% after SR at three years, p = 0.119). CONCLUSION: Compared to SR, NTM-RFA for solitary intermediate-sized HCC was associated with less morbidity and more systematized recurrence, while the rate of local recurrence was not significantly different. Most patients with intrahepatic recurrence remained eligible for rescue therapies, resulting in equivalent long-term oncological results after both treatments. LAY SUMMARY: Outcomes of patients treated for intermediate-sized hepatocellular carcinoma by surgical resection or no-touch multibipolar radiofrequency ablation were compared. No-touch multibipolar radiofrequency ablation was associated with a lower overall morbidity and a higher rate of systematized recurrence within the treated segment or in an adjacent segment within a 2 cm distance from the initial tumor site. Most patients with intrahepatic recurrence remained eligible for rescue curative therapy, enabling them to achieve similar long-term oncological results after both treatments.
引用
- Mohkam K, Dumont PN, Manichon AF, et al. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. J Hepatol. 2018. PMID: 29410287. doi:10.1016/j.jhep.2018.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。